Edition:
India

TG Therapeutics Inc (TGTX.OQ)

TGTX.OQ on NASDAQ Stock Exchange Capital Market

9.60USD
17 Jan 2018
Change (% chg)

-- (--)
Prev Close
$9.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
257,597
52-wk High
$15.35
52-wk Low
$4.10

Chart for

About

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered... (more)

Overall

Beta: 1.34
Market Cap(Mil.): $846.68
Shares Outstanding(Mil.): 68.84
Dividend: --
Yield (%): --

Financials

BRIEF-TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies

* TG THERAPEUTICS AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL BTK INHIBITOR PROGRAM FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES

08 Jan 2018

BRIEF-TG Therapeutics qtrly net loss per common share $0.48

* TG therapeutics, inc. Provides business update and reports third quarter 2017 financial results

08 Nov 2017

BRIEF-TG Therapeutics Inc gives results from phase 2 multicenter trial of TG-1101

* TG Therapeutics Inc - ‍announced results from phase 2 multicenter trial of TG-1101 (ublituximab) in relapsing forms of multiple sclerosis​

26 Oct 2017

BRIEF-TG Therapeutics announces completion of full enrollment in UNITY-CLL phase 3 trial

* TG Therapeutics announces completion of full enrollment in the UNITY-CLL phase 3 trial

16 Oct 2017

BRIEF-TG Therapeutics announces completion of target enrollment

* TG Therapeutics announces completion of target enrollment in the unity-CLL phase 3 trial

05 Sep 2017

BRIEF-TG Therapeutics announces successful outcome from first pre-planned interim analysis

* TG Therapeutics Inc announces successful outcome from the first pre-planned interim analysis by independent DSMB of the DLBCL cohort in the unity-NHL PHASE 2B trial

10 Aug 2017

BRIEF-TG Therapeutics Q2 loss per share ‍$0.45​

* Tg therapeutics Inc provides business update and reports second quarter 2017 financial results

09 Aug 2017

BRIEF-TG therapeutics provides FDA update on multiple sclerosis study

* Announces special protocol assessment (spa) agreement with the FDA for a Phase 3 program of TG-1101 (ublituximab) for patients with multiple sclerosis (MS)

01 Aug 2017

Competitors

Earnings vs. Estimates